Phage therapy: Difference between revisions

From IDWiki
(Created page with "== Background == * Bacteriophages can be used to treat extensively drug-resistant infections, mostly gram-negative bacilli or mycobacteria * Phages need to be trained for the specific bacterium and may be used synergistically with antibiotics == Access == * Process is in development, in Canada * A regulatory nightmare == Canadian Companies == * [https://cytophage.com/ Cytophage] (Winnipeg) * [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based compa...")
 
No edit summary
 
Line 9: Line 9:
 
* A regulatory nightmare
 
* A regulatory nightmare
   
== Canadian Companies ==
+
== Companies ==
   
  +
* Canadian companies
* [https://cytophage.com/ Cytophage] (Winnipeg)
+
** [https://cytophage.com/ Cytophage] (Winnipeg)
* [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based company with site in Montreal)
+
** [http://www.phageluxagrihealth.com/en/ Phagelux] (China-based company with site in Montreal)
  +
* See also the [https://phage.directory/ Phage Directory]
   
 
== Further Reading ==
 
== Further Reading ==

Latest revision as of 18:36, 28 June 2022

Background

  • Bacteriophages can be used to treat extensively drug-resistant infections, mostly gram-negative bacilli or mycobacteria
  • Phages need to be trained for the specific bacterium and may be used synergistically with antibiotics

Access

  • Process is in development, in Canada
  • A regulatory nightmare

Companies

Further Reading

  • Biological foundations of successful bacteriophage therapy. EMBO Mol Med. 2022:e12435.